Dr. Koo is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
515 Spruce St
San Francisco, CA 94118Phone+1 415-476-4701Fax+1 415-502-4126
Education & Training
University of California (San Francisco)Residency, Dermatology, 1985 - 1988
UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Psychiatry, 1982 - 1985- UCLA David Geffen School of Medicine/UCLA Medical CenterInternship, Internal Medicine, 1981 - 1982
Harvard Medical SchoolClass of 1981
Certifications & Licensure
CA State Medical License 1982 - 2026- American Board of Dermatology Dermatology
- American Board of Psychiatry and Neurology Psychiatry
Awards, Honors, & Recognition
- America's Top Doctors Castle Connolly, 2006-2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Super Doctor SuperDoctors.com
Clinical Trials
- Study of a New Dressing for Use With Topical Medications Start of enrollment: 2005 Sep 01
- Open Label Study of Alefacept Injections to Patients With Moderate to Severe Psoriasis Start of enrollment: 2007 Sep 01
- Open Label Study Etanercept's Maintenance Dose in Obese Patients With Moderate to Severe Plaque Type Psoriasis Start of enrollment: 2008 Oct 01
- Join now to see all
Publications & Presentations
PubMed
- Boxed warnings for dermatologic JAK inhibitors: are they standardized worldwide?Shayla Nguyen, Nicholas Brownstone, John Koo
The Journal of Dermatological Treatment. 2024-12-01 - Long-term quality of life outcomes from a phase 4 study of tildrakizumab in patients with moderate-to-severe plaque psoriasis in a real-world setting.Neal Bhatia, Jayme Heim, J Gabriel Vasquez, Tina Bhutani, Brad Schenkel
The Journal of Dermatological Treatment. 2024-12-01 - Brodalumab: Six-Year US Pharmacovigilance Report.Mark G Lebwohl, John Y Koo, April W Armstrong, Bruce E Strober, Soo Han Yoon
Dermatology and Therapy. 2024-11-26
Journal Articles
- The Impact of Pediatric Atopic Dermatitis on Families: A ReviewJohn Koo, Tina Bhutani, Pediatric Dermatology
- Dietary Recommendations for Adults with Psoriasis or Psoriatic Arthritis from the Medical Board of the National Psoriasis FoundationRonald Prussick, Johann E Gudjonsson, Alice Gottlieb, John Koo, Jerry Bagel, Adam R Ford, Joseph A Markenson, Wilson Liao, Joseph F Merola, Jashin J Wu, JAMA
Press Mentions
Alopecia’s Impact on Mental HealthMay 15th, 2023- Brodalumab: 4-Year US Pharmacovigilance ReportMarch 14th, 2023
- EPI Health and MC2 Therapeutics Announces U.S. Launch of Wynzora® Cream for Plaque Psoriasis (Calcipotriene and Betamethasone Dipropionate w/w 0.005%/0.064%)July 19th, 2021
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
